CAPEK JOHN M 4
4 · ABBOTT LABORATORIES · Filed Apr 23, 2020
Insider Transaction Report
Form 4
CAPEK JOHN M
Executive Vice President
Transactions
- Exercise/Conversion
Option (right to buy)
2020-04-21−50,100→ 0 totalExercise: $22.39From: 2014-02-18Exp: 2021-02-17→ Common shares (50,100 underlying) - Sale
Common shares without par value
2020-04-21$95.63/sh−31,399$3,002,730→ 335,501 total - Exercise/Conversion
Common shares without par value
2020-04-21$22.39/sh+50,100$1,121,834→ 366,900 total - Sale
Common shares without par value
2020-04-21$96.28/sh−18,701$1,800,596→ 316,800 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.14 to $96.135, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.14 to $96.52, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.